New research from King’s College London has found that ubrogepant – a drug used to manage migraine attacks – can effectively reduce the non-headache related symptoms when taken one to six hours prior to a migraine headache beginning.
By
NIHR Maudsley BRC at 14 May 2025
New research from the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial has found that low-dose interleukin-2 (IL2LD) is both safe and effective for use on people with Motor Neurone Disease (MND), also known as amyotrophic lateral sclerosis (ALS) compared to placebo.
By
NIHR Maudsley BRC at 12 May 2025
An artificial intelligence (AI) model is being trained on a set of NHS data for 57 million people in England, from which personal information has been stripped away. The pilot study is being run by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and University College London (UCL). The model could transform patient care, identifying opportunities where early interventions might significantly improve or save lives.
By
NIHR Maudsley BRC at 7 May 2025
The Independent Scientific Advisory Panel is a core part of the governance framework for our NIHR Maudsley BRC, providing advice and a means for scientific accountability, in parallel with the central accountability to the NIHR. The Panel is chaired by Dr Helen Munn OBE.
By
NIHR Maudsley BRC at 24 Apr 2025
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) King’s College London has shown that a biological brain mechanism called the ‘kynurenine pathway’ is imbalanced in adolescents with depression, and this imbalance is more pronounced in teenage girls than boys.
By
NIHR Maudsley BRC at 25 Mar 2025